(Q34269380)

1 August 2017

title

Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment (English)

1 reference

1 August 2017

1 reference

1 reference

Christine M Walko

1

1 reference

1 August 2017

Howard McLeod

series ordinal

2

1 reference

1 August 2017

publication date

1 April 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

13

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

691-697

1 reference

Adjuvant endocrine therapy for premenopausal women with early breast cancer.

1 August 2017

cites work

1 reference

CYP2D6 and tamoxifen: DNA matters in breast cancer

21 January 2018

1 reference

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

21 January 2018

1 reference

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

21 January 2018

1 reference

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer

21 January 2018

1 reference

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

21 January 2018

1 reference

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

21 January 2018

1 reference

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

21 January 2018

1 reference

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.12.27

1 reference

1 August 2017

1 reference